Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Mantere, Tuomo ^a   Tervasmäki, Anna ^a   Nurmi, Anna ^b   Rapakko, Katrin ^c,d   Kauppila, Saila ^a   Tang, Jiangbo ^e   Schleutker, Johanna ^f,g   Kallioniemi, Anne ^h   Hartikainen, Jaana M ^i,j   Mannermaa, Arto ^i,j   Nieminen, Pentti ^a   Hanhisalo, Riitta ^c   Lehto, Sini ^b   Suvanto, Maija ^b   Grip, Mervi ^a   Jukkola Vuorinen, Arja ^a   Tengström, Maria ^i,j   Auvinen, Päivi ^i,j   Kvist, Anders ^k   Borg, Åke ^k   Blomqvist, Carl ^b,l   Aittomäki, Kristiina ^b   Greenberg, Roger A ^e   Winqvist, Robert ^a   Nevanlinna, Heli ^b   Pylkäs, Katri ^a   more..

^a UNIVERSITY OF OULU   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Laboratory of Cancer Genetics and Tumor Biology   (Finland)

^d LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF TURKU   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h FIMLAB LABORATORIES   (Finland)

ⁱ UNIVERSITY OF EASTERN FINLAND   (Finland)

^j KUOPIO UNIVERSITY HOSPITAL   (Finland)

^k LUND UNIVERSITY   (Sweden)

^l ÖREBRO UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; FANCD2 PROTEIN, HUMAN; FANCONI ANEMIA GROUP D2 PROTEIN; MESSENGER RNA; TEX15 PROTEIN, HUMAN; TUMOR MARKER;

ALLELE; BREAST TUMOR; CASE CONTROL STUDY; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GERMLINE MUTATION; HEREDITARY TUMOR SYNDROME; HUMAN; META ANALYSIS (TOPIC); MUTATION; RNA STABILITY; WORKFLOW;

ALLELES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; DNA DAMAGE; DNA MUTATIONAL ANALYSIS; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; META-ANALYSIS AS TOPIC; MUTATION; NEOPLASTIC SYNDROMES, HEREDITARY; RNA STABILITY; RNA, MESSENGER; WORKFLOW;

EID: 85018442040     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00766-9     Document Type: Article

References (49)

1. Khanna, K. K. & Jackson, S. P. DNA double-strand breaks: Signaling, repair and the cancer connection. Nat. Genet. 27, 247-254 (2001).
2. Hoeijmakers, J. H. J. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374 (2001).
3. Erkko, H. et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature 446, 316-319 (2007).
4. Pylkäs, K. et al. Evaluation of the role of Finnish ataxia-Telangiectasia mutations in hereditary predisposition to breast cancer. Carcinogenesis 28, 1040-1045 (2007).
5. Vahteristo, P. et al. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet. 71, 432-438 (2002).
6. Cybulski, C. et al. Germline RECQL mutations are associated with breast cancer susceptibility. Nat. Genet. 47, 643-646 (2015).
7. Sun, J. et al. Mutations in RECQL Gene Are Associated with Predisposition to Breast Cancer. PLoS Genet. 11 (2015).
8. Kiiski, J. I. et al. Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proc. Natl. Acad. Sci. USA 111, 15172-15177 (2014).
9. Vijai, J. et al. A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer. Cancer. Discov (2016).
10. Couch, F. J., Nathanson, K. L. & Offit, K. Two decades after BRCA: Setting paradigms in personalized cancer care and prevention. Science 343, 1466-1470 (2014).
11. Turnbull, C. & Rahman, N. Genetic predisposition to breast cancer: Past, present, and future. Annual Review of Genomics and Human Genetics 9, 321-345 (2008).
12. Mantere, T. et al. Targeted Next-Generation Sequencing Identifies a Recurrent Mutation in MCPH1 Associating with Hereditary Breast Cancer Susceptibility. PLoS Genet. 12 (2016).
13. Heikkinen, K. et al. RAD50 and NBS1 are breast cancer susceptibility genes associated with genomic instability. Carcinogenesis 27, 1593-1599 (2006).
14. Levy-Lahad, E. Fanconi anemia and breast cancer susceptibility meet again. Nat. Genet. 42, 368-369 (2010).
15. Yang, F., Eckardt, S., Leu, N. A., McLaughlin, K. J. & Wang, P. J. Mouse TEX15 is essential for DNA double-strand break repair and chromosomal synapsis during male meiosis. J. Cell Biol. 180, 673-679 (2008).
16. Stewart, G. S. et al. The RIDDLE Syndrome Protein Mediates a Ubiquitin-Dependent Signaling Cascade at Sites of DNA Damage. Cell 136, 420-434 (2009).
17. Loriot, A., Boon, T. & De Smet, C. Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int. J. Cancer 105, 371-376 (2003).
18. Yamada, R. et al. Preferential expression of cancer/testis genes in cancer stem-like cells: Proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 81, 428-434 (2013).
19. Lonsdale, J. et al. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45, 580-585 (2013).
20. Uhlén, M. et al. Tissue-based map of the human proteome. Science 347 (2015).
21. Huusko, P. et al. Evidence of founder mutations in finnish BRCA1 and BRCA2 families [4]. Am. J. Hum. Genet. 62, 1544-1548 (1998).
22. Rapakko, K. et al. Germline TP53 alterations in Finnish breast cancer families are rare and occur at corserved mutation-prone sites. Br. J. Cancer 84, 116-119 (2001).
23. Nikkilä, J. et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun 4 (2013).
24. Kalb, R. et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am. J. Hum. Genet. 80, 895-910 (2007).
25. Mantere, T. et al. Finnish Fanconi anemia mutations and hereditary predisposition to breast and prostate cancer. Clin. Genet. 88, 68-73 (2015).
26. Couch, F. J. et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J. Clin. Oncol. 33, 304-311 (2015).
27. Chen, S.-R. et al. Androgen receptor in Sertoli cells regulates DNA double-strand break repair and chromosomal synapsis of spermatocytes partially through intercellular EGF-EGFR signaling. Oncotarget 7, 18722-18735 (2016).
28. Okutman, O. et al. Exome sequencing reveals a nonsense mutation in TEX15 causing spermatogenic failure in a Turkish family. Hum. Mol. Genet. 24, 5581-5588 (2015).
29. Lindeboom, R. G., Supek, F. & Lehner, B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat. Genet. 48, 1112-1118 (2016).
30. Sawyer, S. L. et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer. Discov. 5, 135-142 (2015).
31. D'Andrea, A. D. Susceptibility pathways in Fanconi's anemia and breast cancer. N. Engl. J. Med. 362, 1909-1919+1862 (2010).
32. Seal, S. et al. Evaluation of Fanconi Anemia Genes in Familial Breast Cancer Predisposition. Cancer Res. 63, 8596-8599 (2003).
33. Peterlongo, P. et al. FANCM c.5791C > T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Hum. Mol. Genet. 24, 5345-5355 (2015).
34. Thompson, E. R. et al. Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes FANCC and BLM as Potential Breast Cancer Susceptibility Alleles. PLoS Genetics 8 (2012).
35. Fagerholm, R. et al. Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer. Ann. Oncol. 24, 2780-2785 (2013).
36. Barroso, E. et al. FANCD2 associated with sporadic breast cancer risk. Carcinogenesis 27, 1930-1937 (2006).
37. Devgan, S. S. et al. Homozygous deficiency of ubiquitin-ligase ring-finger protein RNF168 mimics the radiosensitivity syndrome of ataxia-Telangiectasia. Cell Death Differ. 18, 1500-1506 (2011).
38. Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285-291 (2016).
39. Ashburner, M. et al. Gene ontology: Tool for the unification of biology. Nat. Genet. 25, 25-29 (2000).
40. Szklarczyk, D. et al. The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-D568 (2011).
41. Chang, X. & Wang, K. Wannovar: Annotating genetic variants for personal genomes via the web. J. Med. Genet. 49, 433-436 (2012).
42. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
43. Brunet, J. Hereditary breast cancer and genetic counseling in young women. Breast Cancer Res. Treat. 123, 7-9 (2010).
44. Syrjäkoski, K. et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected finnish breast cancer patients. J. Natl. Cancer Inst. 92, 1529-1531 (2000).
45. Kilpivaara, O. et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int. J. Cancer 113, 575-580 (2005).
46. Fagerholm, R. et al. NAD(P)H:quinone oxidoreductase 1 NQO1 2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40, 844-853 (2008).
47. Eerola, H., Blomqvist, C., Pukkala, E., Pyrhönen, S. & Nevanlinna, H. Familial breast cancer in southern Finlandhow prevalent are breast cancer families and can we trust the family history reported by patients? Eur. J. Cancer 36, 1143-1148 (2000).
48. Kuusisto, K. M., Bebel, A., Vihinen, M., Schleutker, J. & Sallinen, S. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals. Breast Cancer Research 13 (2011).
49. Hartikainen, J. M. et al. Refinement of the 22q12-q13 breast cancer-Associated region: Evidence of TMPRSS6 as a candidate gene in an eastern Finnish population. Clinical Cancer Research 12, 1454-1462 (2006).